nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.0889	0.0995	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0438	0.049	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors—NR1I2—bone cancer	0.0401	0.0448	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0393	0.044	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0377	0.0421	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors—NR1I2—bone cancer	0.0359	0.0402	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—NR1I2—bone cancer	0.0345	0.0386	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—NR1I2—bone cancer	0.0345	0.0386	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0317	0.0354	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0284	0.0318	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0272	0.0305	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0272	0.0305	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.0256	0.0286	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.023	0.0257	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.022	0.0246	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0167	0.0186	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—ZNF77—bone cancer	0.0162	0.0181	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0159	0.0178	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—ZNF77—bone cancer	0.0145	0.0162	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ZNF77—bone cancer	0.0139	0.0155	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ZNF77—bone cancer	0.0139	0.0155	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.0109	0.0122	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00818	0.00916	CbGpPWpGaD
Tazarotene—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.00804	0.009	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00785	0.00878	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ZNF77—bone cancer	0.00778	0.00871	CbGpPWpGaD
Tazarotene—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00774	0.00866	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.00717	0.00803	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—MDM2—bone cancer	0.00709	0.00793	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ZNF77—bone cancer	0.00698	0.00781	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00696	0.00779	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ZNF77—bone cancer	0.00669	0.00749	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ZNF77—bone cancer	0.00669	0.00749	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00667	0.00747	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00634	0.00709	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—JUN—bone cancer	0.00616	0.0069	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00608	0.0068	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00577	0.00646	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00569	0.00637	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00553	0.00619	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.00552	0.00618	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—NR1I2—bone cancer	0.00547	0.00612	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00546	0.00611	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NR1I2—bone cancer	0.00491	0.00549	CbGpPWpGaD
Tazarotene—Sensitisation—Epirubicin—bone cancer	0.00482	0.0454	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00482	0.0054	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NR1I2—bone cancer	0.0047	0.00526	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NR1I2—bone cancer	0.0047	0.00526	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00462	0.00517	CbGpPWpGaD
Tazarotene—Sensitisation—Doxorubicin—bone cancer	0.00446	0.042	CcSEcCtD
Tazarotene—Leukoderma—Methotrexate—bone cancer	0.00433	0.0407	CcSEcCtD
Tazarotene—RARA—Adipogenesis—RB1—bone cancer	0.00406	0.00454	CbGpPWpGaD
Tazarotene—Leukoderma—Epirubicin—bone cancer	0.00405	0.0381	CcSEcCtD
Tazarotene—RARG—Gene Expression—FUS—bone cancer	0.0038	0.00425	CbGpPWpGaD
Tazarotene—Leukoderma—Doxorubicin—bone cancer	0.00375	0.0353	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00358	0.004	CbGpPWpGaD
Tazarotene—Pain—Carboplatin—bone cancer	0.00349	0.0328	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00343	0.00384	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—FUS—bone cancer	0.00341	0.00381	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00334	0.00374	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0033	0.00369	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—FUS—bone cancer	0.00327	0.00366	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—FUS—bone cancer	0.00327	0.00366	CbGpPWpGaD
Tazarotene—Skin exfoliation—Cisplatin—bone cancer	0.0032	0.0301	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methotrexate—bone cancer	0.0031	0.0291	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Epirubicin—bone cancer	0.0029	0.0273	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00271	0.00303	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Doxorubicin—bone cancer	0.00268	0.0252	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00265	0.00297	CbGpPWpGaD
Tazarotene—Burning sensation—Methotrexate—bone cancer	0.00265	0.0249	CcSEcCtD
Tazarotene—RARG—Gene Expression—NR1I2—bone cancer	0.00263	0.00295	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00256	0.00286	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00254	0.00285	CbGpPWpGaD
Tazarotene—Burning sensation—Epirubicin—bone cancer	0.00248	0.0233	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00245	0.00274	CbGpPWpGaD
Tazarotene—Blister—Epirubicin—bone cancer	0.00239	0.0225	CcSEcCtD
Tazarotene—RARB—Gene Expression—NR1I2—bone cancer	0.00236	0.00264	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.00231	0.00258	CbGpPWpGaD
Tazarotene—Burning sensation—Doxorubicin—bone cancer	0.00229	0.0216	CcSEcCtD
Tazarotene—RARA—Gene Expression—NR1I2—bone cancer	0.00226	0.00253	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NR1I2—bone cancer	0.00226	0.00253	CbGpPWpGaD
Tazarotene—Blister—Doxorubicin—bone cancer	0.00221	0.0208	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.00221	0.00247	CbGpPWpGaD
Tazarotene—Stinging—Epirubicin—bone cancer	0.00213	0.02	CcSEcCtD
Tazarotene—Skin discolouration—Methotrexate—bone cancer	0.00204	0.0192	CcSEcCtD
Tazarotene—Stinging—Doxorubicin—bone cancer	0.00197	0.0185	CcSEcCtD
Tazarotene—RARG—Gene Expression—EIF2S1—bone cancer	0.00195	0.00218	CbGpPWpGaD
Tazarotene—Skin discolouration—Epirubicin—bone cancer	0.00191	0.0179	CcSEcCtD
Tazarotene—Inflammation—Methotrexate—bone cancer	0.0019	0.0179	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.00181	0.00203	CbGpPWpGaD
Tazarotene—Inflammation—Epirubicin—bone cancer	0.00178	0.0167	CcSEcCtD
Tazarotene—Skin discolouration—Doxorubicin—bone cancer	0.00177	0.0166	CcSEcCtD
Tazarotene—Skin exfoliation—Methotrexate—bone cancer	0.00176	0.0165	CcSEcCtD
Tazarotene—RARB—Gene Expression—EIF2S1—bone cancer	0.00174	0.00195	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.00174	0.00194	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.00171	0.00192	CbGpPWpGaD
Tazarotene—Dermatitis contact—Epirubicin—bone cancer	0.0017	0.016	CcSEcCtD
Tazarotene—RARG—Gene Expression—EZH2—bone cancer	0.00169	0.00189	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EIF2S1—bone cancer	0.00167	0.00187	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EIF2S1—bone cancer	0.00167	0.00187	CbGpPWpGaD
Tazarotene—Skin exfoliation—Epirubicin—bone cancer	0.00164	0.0155	CcSEcCtD
Tazarotene—Inflammation—Doxorubicin—bone cancer	0.00164	0.0155	CcSEcCtD
Tazarotene—Dermatitis contact—Doxorubicin—bone cancer	0.00158	0.0148	CcSEcCtD
Tazarotene—Skin exfoliation—Doxorubicin—bone cancer	0.00152	0.0143	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.00152	0.0017	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—EZH2—bone cancer	0.00152	0.0017	CbGpPWpGaD
Tazarotene—Erythema—Cisplatin—bone cancer	0.00147	0.0138	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.00146	0.00163	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EZH2—bone cancer	0.00145	0.00163	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EZH2—bone cancer	0.00145	0.00163	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.00144	0.00161	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.00142	0.00159	CbGpPWpGaD
Tazarotene—Eczema—Epirubicin—bone cancer	0.00139	0.0131	CcSEcCtD
Tazarotene—Dermatitis bullous—Epirubicin—bone cancer	0.00131	0.0123	CcSEcCtD
Tazarotene—Eczema—Doxorubicin—bone cancer	0.00129	0.0121	CcSEcCtD
Tazarotene—Discomfort—Cisplatin—bone cancer	0.00123	0.0116	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.00123	0.00138	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.00121	0.00136	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Doxorubicin—bone cancer	0.00121	0.0114	CcSEcCtD
Tazarotene—Oedema—Cisplatin—bone cancer	0.0012	0.0113	CcSEcCtD
Tazarotene—Dry skin—Epirubicin—bone cancer	0.00115	0.0108	CcSEcCtD
Tazarotene—Dry skin—Doxorubicin—bone cancer	0.00106	0.00998	CcSEcCtD
Tazarotene—Photosensitivity reaction—Methotrexate—bone cancer	0.00105	0.00992	CcSEcCtD
Tazarotene—Pain—Cisplatin—bone cancer	0.00102	0.00963	CcSEcCtD
Tazarotene—Photosensitivity reaction—Epirubicin—bone cancer	0.000987	0.00928	CcSEcCtD
Tazarotene—Haemoglobin—Methotrexate—bone cancer	0.000929	0.00874	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—bone cancer	0.000925	0.0087	CcSEcCtD
Tazarotene—Photosensitivity reaction—Doxorubicin—bone cancer	0.000913	0.00859	CcSEcCtD
Tazarotene—Haemoglobin—Epirubicin—bone cancer	0.00087	0.00818	CcSEcCtD
Tazarotene—Haemorrhage—Epirubicin—bone cancer	0.000865	0.00814	CcSEcCtD
Tazarotene—CYP2C8—Metabolism—NDUFA12—bone cancer	0.000862	0.000965	CbGpPWpGaD
Tazarotene—Oedema peripheral—Epirubicin—bone cancer	0.000852	0.00802	CcSEcCtD
Tazarotene—Erythema—Methotrexate—bone cancer	0.000805	0.00757	CcSEcCtD
Tazarotene—Haemoglobin—Doxorubicin—bone cancer	0.000805	0.00757	CcSEcCtD
Tazarotene—Haemorrhage—Doxorubicin—bone cancer	0.000801	0.00753	CcSEcCtD
Tazarotene—Oedema peripheral—Doxorubicin—bone cancer	0.000789	0.00742	CcSEcCtD
Tazarotene—Rash—Cisplatin—bone cancer	0.000755	0.0071	CcSEcCtD
Tazarotene—Dermatitis—Cisplatin—bone cancer	0.000754	0.00709	CcSEcCtD
Tazarotene—Erythema—Epirubicin—bone cancer	0.000753	0.00709	CcSEcCtD
Tazarotene—CYP2C8—Metabolism—NT5C3A—bone cancer	0.000714	0.000799	CbGpPWpGaD
Tazarotene—Erythema—Doxorubicin—bone cancer	0.000697	0.00656	CcSEcCtD
Tazarotene—Discomfort—Methotrexate—bone cancer	0.000677	0.00637	CcSEcCtD
Tazarotene—Discomfort—Epirubicin—bone cancer	0.000634	0.00596	CcSEcCtD
Tazarotene—Oedema—Epirubicin—bone cancer	0.000615	0.00578	CcSEcCtD
Tazarotene—Discomfort—Doxorubicin—bone cancer	0.000586	0.00551	CcSEcCtD
Tazarotene—Oedema—Doxorubicin—bone cancer	0.000569	0.00535	CcSEcCtD
Tazarotene—Pain—Methotrexate—bone cancer	0.000562	0.00528	CcSEcCtD
Tazarotene—Pain—Epirubicin—bone cancer	0.000526	0.00495	CcSEcCtD
Tazarotene—Pain—Doxorubicin—bone cancer	0.000486	0.00458	CcSEcCtD
Tazarotene—Pruritus—Methotrexate—bone cancer	0.000465	0.00437	CcSEcCtD
Tazarotene—Pruritus—Epirubicin—bone cancer	0.000435	0.00409	CcSEcCtD
Tazarotene—Rash—Methotrexate—bone cancer	0.000414	0.0039	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—bone cancer	0.000414	0.00389	CcSEcCtD
Tazarotene—Pruritus—Doxorubicin—bone cancer	0.000402	0.00379	CcSEcCtD
Tazarotene—Rash—Epirubicin—bone cancer	0.000388	0.00365	CcSEcCtD
Tazarotene—Dermatitis—Epirubicin—bone cancer	0.000387	0.00364	CcSEcCtD
Tazarotene—Rash—Doxorubicin—bone cancer	0.000359	0.00337	CcSEcCtD
Tazarotene—Dermatitis—Doxorubicin—bone cancer	0.000358	0.00337	CcSEcCtD
Tazarotene—CYP2C8—Metabolism—ENO2—bone cancer	0.000313	0.00035	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—DHFR—bone cancer	0.00029	0.000325	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GNA11—bone cancer	0.000271	0.000304	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP3A4—bone cancer	0.000246	0.000275	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000245	0.000274	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTP1—bone cancer	0.00021	0.000235	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS2—bone cancer	0.000109	0.000122	CbGpPWpGaD
